Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Amoxicillin

Preparation Calculator

Amoxicillin

Beta-lactam antibiotic (aminopenicillin)

AdultPediatricHigh Yield

Indication

AOM (non-severe) • Strep pharyngitis • Low-risk CAP (no atypicals) • Susceptible UTI only • H. pylori (combo only)

At a glance

INDICATIONS (CORE USE)

Non-severe AOM; strep pharyngitis (confirmed/high suspicion); low-risk outpatient CAP without atypical coverage; susceptible UTI only; H. pylori (combination regimens only).

ADULT DOSE (STANDARD)

Mild–moderate: 500 mg TID • Severe: 875 mg BID or 1 g TID

MAX DOSE

- ~4 g/day (adjust for renal function)

Route

PO (IV formulations exist for other agents)

PEDIATRIC DOSE

Mild 20–40 mg/kg/day divided • Severe up to 80–90 mg/kg/day (see dosing)

Do not miss

Must-not-miss safety points

Major warning

• Anaphylaxis → immediate IM epinephrine (life-threatening) • EBV infection → high risk of rash (misdiagnosis trap) • β-lactamase organisms → treatment failure unless inhibitor used • Avoid empiric use in high-resistance settings

Indications

Primary

  • Acute otitis media (first-line, non-severe)
  • Streptococcal pharyngitis (confirmed/high suspicion)

Secondary

  • Community-acquired pneumonia (low-risk outpatient, no atypical coverage)
  • Susceptible UTI (only if the organism is likely sensitive; avoid empiric use if resistance is likely)

Other

  • H. pylori eradication (combination therapy only)

Dosing

STANDARD (ADULT PO)

Mild–moderate: 500 mg PO TID Severe: 875 mg PO BID or 1 g PO TID

ADULT DOSE

ADULT — indication-specific: • Susceptible uncomplicated lower UTI: commonly 500 mg TID (align with culture and local protocol) • H. pylori eradication: use only fixed combination regimen doses (e.g., with PPI + second antibiotic) per local protocol

PEDIATRIC DOSE

PEDIATRIC: weight-based dosing only; verify formulation strength and indication-specific daily maximum before prescribing.

  • Mild: 20–40 mg/kg/day divided BID or TID
  • Severe: up to 80–90 mg/kg/day divided per indication

MAX DOSE

MAX DOSE - ~4 g/day (adjust for renal function)

Practical Note

RENAL ADJUSTMENT: • CrCl 10–30 mL/min: extend interval to q12h • CrCl <10 mL/min: q24h • Hemodialysis: give dose after the session

Warnings

Clinical warnings

  • If β-lactamase–producing organisms are suspected → use amoxicillin-clavulanate (also consider when H. influenzae, M. catarrhalis, or resistant UTI is likely)
  • Typical escalation scenarios: recurrent AOM; acute bacterial sinusitis; resistant or higher-risk CAP; animal bites (polymicrobial / β-lactamase risk) — follow local guideline
  • Rash does not equal true penicillin allergy — especially during viral illness; document timing and morphology
  • EBV (e.g., infectious mononucleosis) → high risk of rash — generally avoid
  • Diarrhea is common; if severe or prolonged, monitor for Clostridioides difficile
  • Use caution in severe infection where broader spectrum or non-oral therapy may be required

Adverse effects

  • GI upset (e.g., nausea, diarrhea)
  • Clostridioides difficile infection risk
  • Rash (distinguish benign from serious hypersensitivity patterns in context)
  • Hypersensitivity reactions including anaphylaxis (rare but emergent)

Contraindications

  • Previous severe beta-lactam hypersensitivity (e.g., anaphylaxis, severe cutaneous adverse reactions such as SJS/TEN/DRESS)

Drug interactions

  • Warfarin: monitor INR—interaction magnitude varies by patient
  • Methotrexate: potential interaction — monitor closely; follow local protocol
  • Probenecid may increase beta-lactam levels—context-dependent

Special populations

Pediatrics

Mild 20–40 mg/kg/day divided • Severe up to 80–90 mg/kg/day (see dosing)

Pregnancy

Pregnancy — generally acceptable when clinically indicated; follow local obstetric guidance and product labeling.

Lactation

— compatible with breastfeeding for most infants; follow product labeling.

Renal impairment

CrCl 10–30 mL/min: extend interval to q12h. CrCl <10 mL/min: q24h. Hemodialysis: administer dose after the session; align timing with institutional dialysis and pharmacy protocols.

Hepatic impairment

Generally less dose-limited by hepatic impairment than some other agents, but consider comorbidities and concomitant drugs; follow product labeling.

Elderly

Higher infection severity risk and renal function variability—confirm eGFR/creatinine clearance and medication reconciliation.

Administration

Can be taken with or without food per product labeling. Shake suspension well before each dose; use an accurate measuring device for liquids. Complete the full course when treating confirmed or high-probability bacterial infection unless directed otherwise.

Monitoring

  • No improvement at 48–72h → reassess diagnosis, resistance, or complications (DO NOT continue blindly)
  • Severe diarrhea → evaluate for Clostridioides difficile infection
  • Renal function → monitor during prolonged courses or sustained high-dose use

Overdose / toxicity

Clinical Picture

• GI: nausea, vomiting, diarrhea • Crystalluria (higher risk with dehydration or high urine drug concentration) • Ensure adequate hydration to reduce crystalluria risk • Rare CNS effects (e.g., agitation, confusion, seizures) with very high exposure, especially if renal clearance is impaired

Immediate Actions

Supportive care; maintain hydration and urine output. Track renal function and mental status after large ingestions or when kidney function is reduced. Escalate care for intractable vomiting, oliguria, rising creatinine, declining mental status, or seizures.

Antidote

No specific antidote — supportive care.

Decontamination

Activated charcoal is generally not routinely indicated for therapeutic oral doses—seek poison center guidance for unusual ingestions.

Escalation

Admit or observe when vomiting prevents fluids, renal injury is worsening, or there are seizures or altered consciousness.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Common first-line oral antibiotic for many susceptible infections; allergy history and local resistance patterns should guide empiric use. Do not treat uncomplicated viral URTI with antibiotics.

Safety Warning

Clarify prior penicillin reactions—true anaphylaxis changes risk stratification. Counsel patients to seek emergency care for throat/tongue swelling, wheeze, or circulatory collapse after a dose.

Stewardship

  • Use the narrowest effective spectrum possible for the confirmed or most likely pathogen.

Response & resistance

  • If no improvement — reconsider organism, resistance, and diagnosis; do not increase dose without reassessment — escalate per local guideline

Dose Safety Box

  • Confirm eGFR or CrCl before using standard adult doses in renal impairment.
  • Use an accurate syringe/cup for pediatric liquids; avoid household spoons.
  • Complete prescribed course unless clinical reassessment directs change

Pharmacy Tool

Preparation Calculator

Amoxicillin 50 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Oral absorption is generally good for many formulations; renal elimination contributes importantly; hepatic metabolism is limited relative to many other drug classes.

Mechanism of action

Inhibits bacterial cell wall synthesis by binding penicillin-binding proteins, leading to bactericidal activity against susceptible organisms.

Common brand names

Saudi Arabia

Amoxicillin (SFDA-registered generics), Amoxil (availability varies), Country-specific branded capsules and suspensions

Global

Amoxil, Trimox, Moxatag, Generic amoxicillin

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • First-line oral option for non-severe AOM, streptococcal pharyngitis, and low-risk outpatient CAP when susceptible organisms are likely.
  • Amoxicillin–clavulanate is often preferred when β-lactamase coverage or broader spectrum is needed — plain amoxicillin alone may be insufficient.
  • Resistance varies by site — tie empiric choice to antibiogram, recent cultures, and national stewardship policy.
  • Reconcile penicillin allergy history before starting; documented IgE-mediated allergy changes risk stratification and alternatives.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • IDSA guidelines
  • NICE antimicrobial guidelines
  • Sanford Guide
  • FDA label